Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]RIST4721 Following a Single Oral Dose to Healthy Male Subjects

NCT05023811 is registered in ClinicalTrials.gov with Aristea Therapeutics, Inc. as lead sponsor.

NCT NCT05023811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05023811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]RIST4721 Following a Single Oral Dose to Healthy Male Subjects
Lead sponsor
Aristea Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 11, 2021
Completion date
September 15, 2021
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adme, healthy